185 related articles for article (PubMed ID: 11987487)
1. [CA-125 antigen].
Zakrzewska I
Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
[TBL] [Abstract][Full Text] [Related]
2. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
3. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
4. Significance of tumor marker determinations in the primary therapy of ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2949-51. PubMed ID: 9329572
[TBL] [Abstract][Full Text] [Related]
5. [Tumor marker in ovarian cancer].
Komai K; Nishida T
Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
[TBL] [Abstract][Full Text] [Related]
6. Recurrent ovarian carcinoma: diagnosis and second-line therapy.
Geary M; Foley M; Lenehan P; Murphy J; Fennelly J
Ir Med J; 1995; 88(2):68-70. PubMed ID: 7775151
[TBL] [Abstract][Full Text] [Related]
7. CA125 based diagnosis and therapy in recurrent ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3019-20. PubMed ID: 9329590
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
9. [Tumour markers in epithelial ovarian cancer].
Sparholt MH; Høgdall E; Høgdall CK
Ugeskr Laeger; 2009 Nov; 171(48):3505-9. PubMed ID: 19944049
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
[TBL] [Abstract][Full Text] [Related]
11. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers and ovarian cysts].
Vinatier D; Houfflin V; Collinet P
J Gynecol Obstet Biol Reprod (Paris); 2001 Nov; 30(1 Suppl):S34-40. PubMed ID: 11917374
[TBL] [Abstract][Full Text] [Related]
13. [Follow-up of treated cancers of the ovary].
Pecking A; Pichon MF
Rev Prat; 1997 Jun; 47(11):1211-5. PubMed ID: 9238817
[TBL] [Abstract][Full Text] [Related]
14. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
Usui N; Suzuki M; Takada M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
[TBL] [Abstract][Full Text] [Related]
15. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
16. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
[TBL] [Abstract][Full Text] [Related]
18. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
19. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
20. [Ovarian cancers and CA 125 in 2006].
Lambaudie E; Collinet P; Vinatier D
Gynecol Obstet Fertil; 2006 Mar; 34(3):254-7. PubMed ID: 16529967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
